<DOC>
	<DOCNO>NCT03071341</DOCNO>
	<brief_summary>AGT-181 fusion protein contain alpha-L-iduronidase intend deliver enzyme peripherally brain , administer intravenously . This long term safety tolerability study AGT-181 patient MPS I complete previous 26-week study , AGT-181-101 . Information biological activity investigational drug also collect .</brief_summary>
	<brief_title>Extension Study Evaluating Long Term Safety Activity AGT-181 Children With MPS I</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>2 year age old ( less 18 ) Must previously enrol study AGT181101 Written consent assent require Female patient must pregnant , willing utilize appropriate birth control method undergo pregnancy test study Refusal complete assessment Pregnant Lactating Received investigational drug within 1 year prior study enrollment Medical condition extenuate circumstance , opinion investigator , may interfere study compliance Clinically significant spinal cord compression evidence cervical instability ( i.e . expect require intervention study participation ) Has develop clinically relevant hypersensitivity/anaphylactoid reaction AGT181</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPS I ; Hurler Syndrome</keyword>
</DOC>